What are the main products offered?

Main products include Dextrose 5% Injection, Dextrose 10% Injection, Ringer Lactate Injection, and Metronidazole Injection.

What are the accepted payment terms?

We accept LC and T/T as terms of payment.

What is the average lead time during peak season?

The peak season lead time is one month.

IV Fluids IV Solution Parenteral Solution

Name: IV Fluids IV Solution Parenteral Solution
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 742398862

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.14-0.30

20,000 Pieces

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Model NO.

100ml~1000ml

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Production Line

GMP Approved

Transport Package

Glass Bottle, Plastic Bottle, Plastic Bag

Specification

50ml~1000ml

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

Wide Volume Range: Manufactures large volume injections in 50ml, 100ml, 250ml, 500ml, and 1000ml options.

Diverse Packaging: Available in glass bottles, plastic bottles, and soft plastic bags for infusion.

GMP Approved Production: Production line certified by SFDA of China with GMP approval standards.

High Annual Output: Yearly output exceeds 1200 million bottles, including 40 million soft plastic bottles.

Leading Market Position: Quality, variety, and output rank among the leading positions in China's field.

Global Market Reach: Products exported to South America, Africa, Asia, Southeast Asia, Oceania, and Middle East.

Established Manufacturer: Company established in 1948 with over 3000 employees and USD 58 million capital.

Comprehensive Product Line: Produces 7 series medicines including infusions, capsules, granules, tablets, and oral liquids.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.